Get the Stockscreener App
49.00
1.03%
-0.51
After Hours:
49.00
Supernus Pharmaceuticals Inc stock is traded at $49.00, with a volume of 1.05M.
It is down -1.03% in the last 24 hours and up +6.04% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$49.51
Open:
$49.39
24h Volume:
1.05M
Relative Volume:
1.28
Market Cap:
$2.75B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
45.81
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
+1.34%
1M Performance:
+6.04%
6M Performance:
+57.71%
1Y Performance:
+53.65%
1-Day Range:
$48.27
$49.81
1-Week Range:
$47.27
$51.78
52-Week Range:
$29.16
$51.78
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
49.00 | 2.78B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Supernus Pharmaceuticals Shares Rise After Piper Sandler Upgrade - MarketScreener
Supernus Pharmaceuticals: A Rising Pharma Contender? - StocksToTrade
Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know - TradingView
SUPN: Piper Sandler Raises Price Target to $65 and Upgrades Rati - GuruFocus
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40 - MarketScreener
Can Supernus Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com
How Supernus Pharmaceuticals Inc. stock performs during Fed tightening cycles2025 Market Outlook & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-10-09 05:01:01 - newser.com
Supernus (SUPN) Receives Upgraded Rating Amid Promising Product Outlook - GuruFocus
How to use Fibonacci retracement on Supernus Pharmaceuticals Inc.2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Is now a turning point for Supernus Pharmaceuticals Inc.July 2025 Earnings & Real-Time Sentiment Analysis - newser.com
Supernus Pharmaceuticals Hits New 52-Week High of $49.66 - Markets Mojo
Will Supernus Pharmaceuticals Inc. rebound enough to break evenDollar Strength & Weekly Top Performers Watchlists - newser.com
How geopolitical tensions affect Supernus Pharmaceuticals Inc. stockCPI Data & Comprehensive Market Scan Insights - newser.com
Why Supernus Pharmaceuticals Inc. stock could be next big winnerJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Using R and stats models for Supernus Pharmaceuticals Inc. forecasting2025 Macro Impact & Reliable Volume Spike Trade Alerts - newser.com
Is Supernus Pharmaceuticals Inc. stock poised for growthPortfolio Growth Summary & Real-Time Market Trend Scan - newser.com
Is Supernus Pharmaceuticals Inc. stock cheap compared to fundamentalsAnalyst Upgrade & Daily Stock Trend Reports - newser.com
Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Hold - Defense World
Smart tools for monitoring Supernus Pharmaceuticals Inc.’s price actionQuarterly Portfolio Review & High Conviction Buy Zone Alerts - newser.com
Real time social sentiment graph for Supernus Pharmaceuticals Inc.Trade Volume Summary & Real-Time Buy Zone Alerts - newser.com
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by GAMMA Investing LLC - Defense World
What MACD signals say about Supernus Pharmaceuticals Inc.Market Volume Summary & Low Drawdown Momentum Trade Ideas - newser.com
Supernus Pharmaceuticals stock hits 52-week high at 48.47 USD - Investing.com India
Supernus Pharmaceuticals stock hits 52-week high at 48.47 USD By Investing.com - Investing.com Australia
Supernus Pharmaceuticals (SUPN): Is the Current Share Price a Fair Reflection of Its True Valuation? - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 18% CAGR over the last five years - simplywall.st
Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $63.00 Price Target at Cantor Fitzgerald - Defense World
Supernus Pharmaceuticals Hits New 52-Week High of $48.00 - Markets Mojo
SUPN: Cantor Fitzgerald Increases Price Target to $63, Maintains Overweight Rating | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):